Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Follow-Up Questions
Qui est le CEO de Virax Biolabs Group Ltd ?
Mr. James Foster est le Chairman of the Board de Virax Biolabs Group Ltd, il a rejoint l'entreprise depuis 2025.
Quelle est la performance du prix de l'action VRAX ?
Le prix actuel de VRAX est de $0.52, il a increased de 1.96% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Virax Biolabs Group Ltd ?
Virax Biolabs Group Ltd appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Virax Biolabs Group Ltd ?
La capitalisation boursière actuelle de Virax Biolabs Group Ltd est de $2.2M
